Not available
Quote | Transgene S.A. (OTCMKTS:TRGNF)
Last: | $1.62 |
---|---|
Change Percent: | 0.0% |
Open: | $1.62 |
Close: | $1.62 |
High: | $1.62 |
Low: | $1.62 |
Volume: | 100 |
Last Trade Date Time: | 10/06/2023 03:00:00 am |
News | Transgene S.A. (OTCMKTS:TRGNF)
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...
Message Board Posts | Transgene S.A. (OTCMKTS:TRGNF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...
Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effect...